Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-trace').style.display = (document.getElementById('cakeErr6802ba51c26a8-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6802ba51c26a8-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-code').style.display = (document.getElementById('cakeErr6802ba51c26a8-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-context').style.display = (document.getElementById('cakeErr6802ba51c26a8-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6802ba51c26a8-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6802ba51c26a8-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26423,
		&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674461,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26423,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Hepatitis C,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26423,
	&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674461,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26423
$metaTitle = &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;
$metaKeywords = &#039;Access to Healthcare,Hepatitis C,medicines&#039;
$metaDesc = &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh | Im4change.org</title>
    <meta name="description" content="
-Down to Earth


Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Down to Earth</div><p align="justify"><em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em></p><p align="justify">Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.</p><p align="justify">BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br /> <br />Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.</p><p align="justify">Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.</p><p align="justify">BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.</p><p align="justify">BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.</p><p align="justify">&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-trace').style.display = (document.getElementById('cakeErr6802ba51c26a8-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6802ba51c26a8-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-code').style.display = (document.getElementById('cakeErr6802ba51c26a8-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-context').style.display = (document.getElementById('cakeErr6802ba51c26a8-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6802ba51c26a8-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6802ba51c26a8-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26423,
		&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674461,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26423,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Hepatitis C,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26423,
	&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674461,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26423
$metaTitle = &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;
$metaKeywords = &#039;Access to Healthcare,Hepatitis C,medicines&#039;
$metaDesc = &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh | Im4change.org</title>
    <meta name="description" content="
-Down to Earth


Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Down to Earth</div><p align="justify"><em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em></p><p align="justify">Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.</p><p align="justify">BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br /> <br />Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.</p><p align="justify">Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.</p><p align="justify">BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.</p><p align="justify">BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.</p><p align="justify">&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-trace').style.display = (document.getElementById('cakeErr6802ba51c26a8-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6802ba51c26a8-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-code').style.display = (document.getElementById('cakeErr6802ba51c26a8-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6802ba51c26a8-context').style.display = (document.getElementById('cakeErr6802ba51c26a8-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6802ba51c26a8-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6802ba51c26a8-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26423,
		&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674461,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26423,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Healthcare,Hepatitis C,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26423,
	&#039;title&#039; =&gt; &#039;New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-Down to Earth
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt;
 &lt;br /&gt;
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674461,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26423
$metaTitle = &#039;LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh&#039;
$metaKeywords = &#039;Access to Healthcare,Hepatitis C,medicines&#039;
$metaDesc = &#039;
-Down to Earth


Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-Down to Earth&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Pharma company&#039;s strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)&#039;s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.&lt;br /&gt; &lt;br /&gt;Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine&#039;s patent ends in 2027.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Criticising tiered pricing as a marketing strategy, international non-profit M&amp;eacute;decins Sans Fronti&amp;egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world&#039;s poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &amp;quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&amp;quot; said a release by the organisation.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&amp;quot; said Rohit Malpani, director of policy and analysis, M&amp;eacute;decins Sans Fronti&amp;egrave;res Access Campaign. Criticising BMS&#039; secrecy of pricing, he added, &amp;quot;BMS&#039; secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&amp;quot;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh | Im4change.org</title>
    <meta name="description" content="
-Down to Earth


Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-Down to Earth</div><p align="justify"><em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em></p><p align="justify">Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.</p><p align="justify">BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br /> <br />Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.</p><p align="justify">Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.</p><p align="justify">BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.</p><p align="justify">BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.</p><p align="justify">&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26423,
		'title' => 'New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh',
		'subheading' => '',
		'description' => '<div align="justify">
-Down to Earth
</div>
<p align="justify">
<em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em>
</p>
<p align="justify">
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
</p>
<p align="justify">
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br />
 <br />
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.
</p>
<p align="justify">
Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.
</p>
<p align="justify">
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
</p>
<p align="justify">
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
</p>
<p align="justify">
&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;
</p>',
		'credit_writer' => 'Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674461,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26423,
	'metaTitle' => 'LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh',
	'metaKeywords' => 'Access to Healthcare,Hepatitis C,medicines',
	'metaDesc' => '
-Down to Earth


Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell...',
	'disp' => '<div align="justify">-Down to Earth</div><p align="justify"><em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em></p><p align="justify">Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.</p><p align="justify">BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br /> <br />Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.</p><p align="justify">Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.</p><p align="justify">BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.</p><p align="justify">BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.</p><p align="justify">&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26423,
	'title' => 'New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh',
	'subheading' => '',
	'description' => '<div align="justify">
-Down to Earth
</div>
<p align="justify">
<em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em>
</p>
<p align="justify">
Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.
</p>
<p align="justify">
BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br />
 <br />
Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.
</p>
<p align="justify">
Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.
</p>
<p align="justify">
BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.
</p>
<p align="justify">
BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.
</p>
<p align="justify">
&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;
</p>',
	'credit_writer' => 'Down to Earth, 6 November, 2014, http://www.downtoearth.org.in/content/new-hepatitis-drug-cost-more-middle-income-nations-activists-cry-foul',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'new-hepatitis-drug-to-cost-more-in-middle-income-nations-activists-cry-foul-jyotsna-singh-4674461',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674461,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26423
$metaTitle = 'LATEST NEWS UPDATES | New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh'
$metaKeywords = 'Access to Healthcare,Hepatitis C,medicines'
$metaDesc = '
-Down to Earth


Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide


Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell...'
$disp = '<div align="justify">-Down to Earth</div><p align="justify"><em>Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide</em></p><p align="justify">Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment.</p><p align="justify">BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation.<br /> <br />Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027.</p><p align="justify">Criticising tiered pricing as a marketing strategy, international non-profit M&eacute;decins Sans Fronti&egrave;res (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. &quot;The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket,&quot; said a release by the organisation.</p><p align="justify">BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt.</p><p align="justify">BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug.</p><p align="justify">&quot;Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can,&quot; said Rohit Malpani, director of policy and analysis, M&eacute;decins Sans Fronti&egrave;res Access Campaign. Criticising BMS' secrecy of pricing, he added, &quot;BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world.&quot;</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for the drug and set different prices for different countries, depending on macroeconomic factors for each nation. Speculation among international health groups, who are following the developments, is that the company would price the drug at a whopping $80,000 for one course of treatment of three months and would sell it at a lower price to developing nations. The production cost for Daclatasvir, according to a study by Andrew Hill of Liverpool University, is as little as $10 - 30 for a three months course. The medicine's patent ends in 2027. Criticising tiered pricing as a marketing strategy, international non-profit Médecins Sans Frontières (MCF) said that due to it, middle-income countries - where nearly three-quarters of the world's poor, and over 70 per cent of Hepatitis C patients live - would be required to pay high prices. "The drugs would be unaffordable for treatment providers such as MSF, governments, and patients who must pay for medicines out of their pocket," said a release by the organisation. BMS also announced that it is ready to negotiate voluntary licenses which allow select generic manufacturers to market cheaper versions of a drug. But these generic manufacturers will be allowed to sell only in 90 developing countries. Countries like China and Egypt, which have a very high HCV burden, are being left out. China has the highest number of Hepatitis C patients in the world, followed by India and Egypt. BMS had also indicated that it did not have plans to register the drug worldwide. This would seriously hinder access in those countries where the company chooses not to register the drug. "Affordable access to Daclatasvir has been intentionally blocked from most middle-income countries, with BMS keen to extract as much profit as it possibly can," said Rohit Malpani, director of policy and analysis, Médecins Sans Frontières Access Campaign. Criticising BMS' secrecy of pricing, he added, "BMS' secrecy portends an unwelcome approach that does not respond to the urgent need for affordable access to Hepatitis C drugs for millions of people across the developing world."